QUIZARTINIB

SynDRA canonical compound SYN0020171 — structure-anchored drug synonym record

Clinical phase	Phase 3
Approval status	Approved · Rx/OTC
Primary target(s)	RET
Mechanism of action	FLT3 inhibitor

All known targets

FLT3
CSF1R
KIT
RET
PDGFRB
PDGFRA
NTRK2
MUSK
MYH10
MYLK
MYLK3
NTRK1

Mechanisms of action (all sources)

FLT3 INHIBITOR
CSF1R INHIBITOR
Macrophage colony stimulating factor receptor inhibitor
Tyrosine-protein kinase receptor FLT3 inhibitor
KIT INHIBITOR
Stem cell growth factor receptor inhibitor
PDGFRB INHIBITOR
Platelet-derived growth factor receptor inhibitor
PDGFRA INHIBITOR
RET INHIBITOR
Tyrosine-protein kinase receptor RET inhibitor

Bioactivity evidence (ChEMBL activities table — not curator-asserted)

Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)

CCNH
NR1I3

Drug classes

Antineoplastic Agents
Tyrosine Kinase Inhibitors

ATC classes

L01E · PROTEIN KINASE INHIBITORS

Cross-references

PubChem CID: 24889392
ChEMBL: CHEMBL576982
DrugBank: DB12874
ChEBI: CHEBI:90217
KEGG: D09956
RxNorm: 2643048
PDB: P30
Wikipedia: Quizartinib
TTD: D07KYT
LINCS BRD: BRD-K93918653

Synonyms

Look up QUIZARTINIB in the interactive SynDRA portal →